{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:54:16Z","timestamp":1790729656312,"version":"4.1.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","trasci.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion and Apheresis Science"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.transci.2018.05.020","type":"journal-article","created":{"date-parts":[[2018,5,16]],"date-time":"2018-05-16T19:21:14Z","timestamp":1526498474000},"page":"363-369","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Usefulness of chromogenic assays for potency assignment and recovery of plasma-derived FVIII and FIX concentrates or their recombinant long acting therapeutic equivalents with potential application in treated pediatric hemophiliac patients"],"prefix":"10.1016","volume":"57","author":[{"given":"Jean","family":"Amiral","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerard","family":"Seghatchian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"June (11)","key":"10.1016\/j.transci.2018.05.020_bib0005","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1182\/blood.V81.11.2925.2925","article-title":"Biochemical, immunological, and in vivo functional characterization of B-domain-deleted factor VIII","volume":"81","author":"Pittman","year":"1993","journal-title":"Blood"},{"issue":"July (7)","key":"10.1016\/j.transci.2018.05.020_bib0010","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1046\/j.1538-7836.2004.00710.x","article-title":"The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977-99","volume":"2","author":"Darby","year":"2004","journal-title":"J Thromb Haemost"},{"issue":"April (4)","key":"10.1016\/j.transci.2018.05.020_bib0015","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.str.2008.03.001","article-title":"Crystal structure of human factor VIII: implications for the formation of the factor IXa-factor VIIIa complex","volume":"16","author":"Ngo","year":"2008","journal-title":"Structure"},{"issue":"April (2)","key":"10.1016\/j.transci.2018.05.020_bib0020","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1751-553X.2007.01021.x","article-title":"Evaluation of three automated chromogenic FVIII kits for the diagnosis of mild discrepant haemophilia A","volume":"31","author":"Rodgers","year":"2009","journal-title":"Int J Lab Hematol"},{"issue":"April (4)","key":"10.1016\/j.transci.2018.05.020_bib0025","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1309\/AJCPMKP94CODILWS","article-title":"NASCOLA proficiency testing committee, laboratory assessment of factor VIII inhibitor titer: the North American specialized coagulation laboratory association experience","volume":"131","author":"Peerschke","year":"2009","journal-title":"Am J Clin Pathol"},{"issue":"Suppl. 1","key":"10.1016\/j.transci.2018.05.020_bib0030","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/jth.12215","article-title":"Gene therapy for hemophilia","volume":"11","author":"Chuah","year":"2013","journal-title":"J Thromb Haemost"},{"issue":"March (2)","key":"10.1016\/j.transci.2018.05.020_bib0035","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/hae.12296","article-title":"Comparative field study evaluating the activity of recombinant factor VIII Fc fusion protein in plasma samples at clinical haemostasis laboratories","volume":"20","author":"Sommer","year":"2014","journal-title":"Haemophilia"},{"issue":"November (5)","key":"10.1016\/j.transci.2018.05.020_bib0040","first-page":"932","article-title":"Comparative field study: impact of laboratory assay variability on the assessment of recombinant factor IX Fc fusion protein (rFIXFc) activity","volume":"112","author":"Sommer","year":"2014","journal-title":"Thromb Haemost"},{"issue":"July (4)","key":"10.1016\/j.transci.2018.05.020_bib0045","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1111\/hae.12634","article-title":"Potency determination of factor VIII and factor IX for new product labelling and postinfusion testing: challenges for caregivers and regulators","volume":"21","author":"Dodt","year":"2015","journal-title":"Haemophilia"},{"issue":"Suppl. 77","key":"10.1016\/j.transci.2018.05.020_bib0050","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/ejh.12500","article-title":"One-stage vs. chromogenic assays in haemophilia A","volume":"94","author":"Potgieter","year":"2015","journal-title":"Eur J Haematol"},{"issue":"March (13)","key":"10.1016\/j.transci.2018.05.020_bib0055","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1182\/blood-2015-01-528414","article-title":"Optimal treatment strategies for hemophilia: achievements and limitations of current prophylactic regimens","volume":"125","author":"Oldenburg","year":"2015","journal-title":"Blood"},{"issue":"June (6)","key":"10.1016\/j.transci.2018.05.020_bib0060","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1111\/jth.12911","article-title":"Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A","volume":"13","author":"Young","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"2015","key":"10.1016\/j.transci.2018.05.020_bib0065","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1182\/asheducation-2015.1.26","article-title":"The long and short of it: using the new factor products","author":"Dunn","year":"2015","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"February (2)","key":"10.1016\/j.transci.2018.05.020_bib0070","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1160\/TH14-02-0180","article-title":"Molecular simulation studies of human coagulation factor VIII C domain-mediated membrane binding","volume":"113","author":"Du","year":"2015","journal-title":"Thromb Haemost"},{"issue":"August (8)","key":"10.1016\/j.transci.2018.05.020_bib0075","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1111\/jth.13375","article-title":"Factor VIII chromogenic assays can be used for potency labeling and postadministration monitoring of N8-GP","volume":"14","author":"Pickering","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"November (6)","key":"10.1016\/j.transci.2018.05.020_bib0080","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1111\/hae.13001","article-title":"A world-wide survey and field study in clinical haemostasis laboratories to evaluate FVIII:C activity assay variability of ADYNOVATE and OBIZUR in comparison with ADVATE","volume":"22","author":"Turecek","year":"2016","journal-title":"Haemophilia"},{"issue":"November (7)","key":"10.1016\/j.transci.2018.05.020_bib0085","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2147\/JBM.S84597","article-title":"Once-weekly prophylactic dosing of recombinant factor IX improves adherence in hemophilia B","volume":"30","author":"Djambas Khayat","year":"2016","journal-title":"J Blood Med"},{"issue":"March (13)","key":"10.1016\/j.transci.2018.05.020_bib0090","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1182\/blood-2015-06-650226","article-title":"A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects","volume":"127","author":"Uchida","year":"2016","journal-title":"Blood"},{"issue":"May (21)","key":"10.1016\/j.transci.2018.05.020_bib0095","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1056\/NEJMoa1511769","article-title":"Factor VIII-mimetic function of humanized bispecific antibody in Hemophilia A","volume":"374","author":"Shima","year":"2016","journal-title":"N Engl J Med"},{"issue":"August (8)","key":"10.1016\/j.transci.2018.05.020_bib0100","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1111\/jth.13375","article-title":"Factor VIII chromogenic assays can be used for potency labeling and postadministration monitoring of N8-GP","volume":"14","author":"Pickering","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"Suppl. 5","key":"10.1016\/j.transci.2018.05.020_bib0105","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/hae.13012","article-title":"Recombinant to modified factor VIII and factor IX - chromogenic and one-stage assays issues","volume":"22","author":"Kitchen","year":"2016","journal-title":"Haemophilia"},{"issue":"Suppl 3","key":"10.1016\/j.transci.2018.05.020_bib0110","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/S0049-3848(16)30414-5","article-title":"The story of A unique molecule in hemophilia A: recombinant single-chain factor VIII","volume":"141","author":"Pabinger-Fasching","year":"2016","journal-title":"Thromb Res"},{"issue":"July (2)","key":"10.1016\/j.transci.2018.05.020_bib0115","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1182\/blood-2015-10-675512","article-title":"FVIII-binding IgG modulates FVIII half-life in patients with severe and moderate hemophilia A without inhibitors","volume":"128","author":"Hofbauer","year":"2016","journal-title":"Blood"},{"issue":"May (5)","key":"10.1016\/j.transci.2018.05.020_bib0120","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1111\/jth.13304","article-title":"Diagnostic and prognostic value of factor VIII binding antibodies in acquired hemophilia A: data from the GTH-AH 01\/2010 study","volume":"14","author":"Werwitzke","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"October (10)","key":"10.1016\/j.transci.2018.05.020_bib0125","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1111\/jth.13787","article-title":"Qualification of a select one-stage activated partial thromboplastin time-based clotting assay and two chromogenic assays for the post-administration monitoring of nonacog beta pegol","volume":"15","author":"Tiefenbacher","year":"2017","journal-title":"J Thromb Haemost"},{"issue":"April (3)","key":"10.1016\/j.transci.2018.05.020_bib0130","first-page":"331","article-title":"Factor activity assays for monitoring extended half-life FVIII and factor IX replacement therapies","volume":"43","author":"Kitchen","year":"2017","journal-title":"Semin Thromb Hemost"},{"issue":"May (5)","key":"10.1016\/j.transci.2018.05.020_bib0135","article-title":"Hemophilia care in the pediatric age","volume":"6","author":"Bertamino","year":"2017","journal-title":"J Clin Med."},{"issue":"February (2)","key":"10.1016\/j.transci.2018.05.020_bib0140","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1177\/2040620717746312","article-title":"Novel therapies and current clinical progress in hemophilia A","volume":"9","author":"Balkaransingh","year":"2018","journal-title":"Ther Adv Hematol"}],"container-title":["Transfusion and Apheresis Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050218301897?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050218301897?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,18]],"date-time":"2019-10-18T00:06:39Z","timestamp":1571357199000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1473050218301897"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["S1473050218301897"],"URL":"https:\/\/doi.org\/10.1016\/j.transci.2018.05.020","relation":{},"ISSN":["1473-0502"],"issn-type":[{"value":"1473-0502","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Usefulness of chromogenic assays for potency assignment and recovery of plasma-derived FVIII and FIX concentrates or their recombinant long acting therapeutic equivalents with potential application in treated pediatric hemophiliac patients","name":"articletitle","label":"Article Title"},{"value":"Transfusion and Apheresis Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transci.2018.05.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}